• IGM Biosciences Inc IGMS.OQ reported a quarterly adjusted loss of 61 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of ten analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from -93 cents to -57 cents per share.

• Revenue fell 36.7% to $412.00 thousand from a year ago; analysts expected $393.75 thousand.

• IGM Biosciences Inc's reported EPS for the quarter was a loss of 61 cents​.

• The company reported a quarterly loss of $36.65 million.

• IGM Biosciences Inc shares had fallen by 77.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00

This summary was machine generated from LSEG data March 7 at 05:09 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)